<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Dopamine-receptor agonists: endocrine; Bromocriptine; Bromocriptine: galactorrhoea; Bromocriptine: acromegaly; Acromegaly; Cabergoline: hyperprolactinaemia; Quinagolide; Lactation, suppression: dopaminergic drugs; Bromocriptine: lactation suppression" /><meta name="IX" content="Dopamine-receptor agonists: endocrine; Bromocriptine; Bromocriptine: galactorrhoea; Bromocriptine: acromegaly; Acromegaly; Cabergoline: hyperprolactinaemia; Quinagolide; Lactation, suppression: dopaminergic drugs; Bromocriptine: lactation suppression" /><title>6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4698-bromocriptine-and-other-dopaminergic-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4698-bromocriptine-and-other-dopaminergic-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4698-bromocriptine-and-other-dopaminergic-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4031-endocrine-system.htm">6 Endocrine system</a> &gt; <a href="PHP4697-other-endocrine-drugs.htm">6.7 Other endocrine drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4697-other-endocrine-drugs.htm" title="Previous: 6.7 Other endocrine drugs">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4705-bromocriptine.htm" title="Next: BROMOCRIPTINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>6.7.1 </span>Bromocriptine and other dopaminergic drugs</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Bromocriptine</strong> is a stimulant of dopamine receptors in the brain; it also inhibits release of prolactin by the pituitary. Bromocriptine is used for the treatment of galactorrhoea, and for the treatment of prolactinomas (when it reduces both plasma prolactin concentration and tumour size). Bromocriptine also inhibits the release of growth hormone and is sometimes used in the treatment of acromegaly, but somatostatin analogues (such as octreotide, <a title=" Somatostatin analogues" href="PHP5801-somatostatin-analogues.htm">section 8.3.4.3</a>) are more effective.</p> <p><strong>Cabergoline</strong> has actions and uses similar to those of bromocriptine, but its duration of action is longer. It has similar side-effects to bromocriptine, however patients intolerant of bromocriptine may be able to tolerate cabergoline (and <em>vice versa</em>).</p> <p><strong>Quinagolide</strong> is a non-ergot dopamine D<sub>2</sub> agonist; it has actions and uses similar to those of ergot-derived dopamine agonists, but its side-effects differ slightly.</p> <div id="PHP4699"><h2>Cautions</h2><p>see notes below; also bromocriptine and cabergoline should be used with caution in patients with a history of peptic ulcer, particularly in acromegalic patients. Treatment should be withdrawn if gastro-intestinal bleeding occurs. In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment). Bromocriptine and cabergoline should be used with caution in patients with Raynaud's syndrome and cardiovascular disease (see also Contra-indications under Bromocriptine, below). Monitor for fibrotic disease (see Fibrotic Reactions, below). Caution is also advised in patients with a history of serious mental disorders (especially psychotic disorders) and in those with acute porpyhria (see <a title="monograph-family: Drugs unsafe for use in acute porphyrias" href="PHP6366-drugs-unsafe-for-use-in-acute-porphyrias.htm">section 9.8.2</a>). Tolerance may be reduced by alcohol.</p></div> <div id="PHP4700"><h2>Contra-indications</h2><p>Bromocriptine and cabergoline should not be used in patients with hypersensitivity to ergot alkaloids. They are contra-indicated in those with cardiac valvulopathy (exclude before treatment, see Fibrotic Reactions). They should also be avoided in pre-eclampsia (see also Contra-indications under Bromocriptine, below).</p></div> <div id="PHP4701"><h2>Side-effects</h2><p>Nausea, constipation, and headache are common side-effects of bromocriptine and cabergoline. Paraesthesia has been reported rarely. Other reported side-effects include hypotension (see also Hypotensive Reactions, below), drowsiness (see also <a title="BNF:target-block: Sudden onset of sleep" href="PHP4698-bromocriptine-and-other-dopaminergic-drugs.htm#PHP4703">Driving</a>, below), dyskinesia, pathological gambling, increased libido, hypersexuality, leg cramps, allergic skin reactions, alopecia, and peripheral oedema. Bromocriptine and cabergoline have been associated with pleuritis, pleural effusion, cardiac valvulopathy, pericardial effusion, constrictive pericarditis, and retroperitoneal, pleural, and pulmonary fibrosis (see Fibrotic Reactions). </p></div> <div class="cI" id="PHP4702"><h3 class="cT">Fibrotic reactions</h3><p>Ergot-derived dopamine-receptor agonists, bromocriptine, cabergoline, lisuride [discontinued], and pergolide have been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.</p><p>Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for chronic endocrine disorders (excludes suppression of lactation) or Parkinson's disease; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline or pergolide should be regularly monitored for cardiac fibrosis, by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).</p></div> <div class="cI" id="PHP4703"> <h3>Driving</h3><div><div class="cE"><h3 class="cT">Sudden onset of sleep</h3> <p class="cT">Excessive daytime sleepiness and sudden onset of sleep can occur with dopaminergic drugs.</p></div><p>Patients starting treatment with these drugs should be warned of the possibility of these effects and of the need to exercise caution when driving or operating machinery.</p><p>Patients who have suffered excessive sedation or sudden onset of sleep should refrain from driving or operating machines until those effects have stopped recurring.</p></div><div><div class="cE"><h3 class="cT">Hypotensive reactions</h3> <p class="cT">Hypotensive reactions can be disturbing in some patients during the first few days of treatment with bromocriptine, cabergoline, or quinagolide—monitor blood pressure for a few days after starting treatment and following dosage increases; particular care should be exercised when driving or operating machinery.</p></div></div></div> <div id="PHP4704"><h2>Suppression of lactation</h2><p>Although bromocriptine and cabergoline are licensed to suppress lactation, they are <strong>not</strong> recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred. Quinagolide is not licensed for the suppression of lactation.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP4705-bromocriptine"><a href="PHP4705-bromocriptine.htm" title="BROMOCRIPTINE">BROMOCRIPTINE</a></li><li id="_PHP4713-cabergoline"><a href="PHP4713-cabergoline.htm" title="CABERGOLINE">CABERGOLINE</a></li><li id="_PHP4720-quinagolide"><a href="PHP4720-quinagolide.htm" title="QUINAGOLIDE">QUINAGOLIDE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4697-other-endocrine-drugs.htm">Previous: 6.7 Other endocrine drugs</a> | <a class="top" href="PHP4698-bromocriptine-and-other-dopaminergic-drugs.htm#">Top</a> | <a accesskey="]" href="PHP4705-bromocriptine.htm">Next: BROMOCRIPTINE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>